ReviewAcute medicine & surgery
Remifentanil use in intensive care units: Current evidence and future perspectives.
Review in Acute medicine & surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Recovery Profiles After MOAA/S-Guided Remifentanil- Versus Fentanyl-Based Propofol Sedation for Gastrointestinal Endoscopy: An IPTW-Adjusted Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Long-Term Recovery After Severe Sepsis: A Case Study of Rhabdomyolysis and Suspected Remifentanil Withdrawal During ICU Recovery.Nursing in critical care · 2026Article
- Remifentanil attenuates LPS-induced hepatic injury by modulating NRF2/HO-1 and necroptosis-related gene expression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Suspected Remifentanil-Induced Hyperalgesia in the ICU With Resolution After Opioid Rotation and no Recurrence on Re-Exposure: A Case Report.Clinical case reports · 2026Article
- Article
- Remifentanil reduces post-induction hypotension compared to fentanyl in thoracoscopic esophagectomy: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- Remifentanil-Induced Chest Wall Rigidity in an Infant With Hepatic Failure.Acute medicine & surgeryArticle
- Remifentanil use in intensive care units: Current evidence and future perspectives.Acute medicine & surgeryReview
- Response to "Remifentanil-Induced Chest Wall Rigidity in an Infant With Hepatic Failure".Acute medicine & surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain management in intensive care units (ICUs) is crucial for improving patient outcomes. Remifentanil, an ultra-short-acting opioid, is metabolized independently of renal and hepatic function, making it an attractive analgesic. This article discusses the pharmacological effects of remifentanil, its usage, and potential side effects in the ICU, current evidence, and clinical situations where its use is preferred. Currently, patients for whom remifentanil use might be considered include (1) post-cardiac surgery patients, (2) patients requiring frequent neurological assessments, (3) patients with hepatic or renal failure, and (4) patients with acute respiratory distress syndrome who are at high risk of self-inflicted lung injury. In these patient groups, remifentanil's unique properties may contribute to effective pain management. However, data on its long-term use in ICUs remains limited. To establish appropriate usage, further research is needed, particularly on withdrawal symptoms, opioid-induced hyperalgesia, and optimal transition strategies following prolonged administration. Furthermore, cost-effectiveness analyses are essential to assess its economic feasibility in ICU settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.